Raquel A. C. Leão
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raquel A. C. Leão has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Rodrigo Octavio Mendonca Alves De Souza
Federal University of Rio de Janeiro
4 shared publications - Felipe L. N. da Silva2 shared publications
- Leandro Soter de Mariz e Miranda
CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France
2 shared publications - Alejandro Mata
Center for Continuous Flow Synthesis and Processing (CCFLOW)
1 shared publication - Alexandre S. França1 shared publication
- C. Oliver Kappe
Institute of Chemistry, University of Graz, NAWI Graz, Heinrichstrasse 28, 8010 Graz, Austria
1 shared publication
Latest Publications
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Process Intensification of Rivaroxaban Key Intermediates: Continuous-Flow Nitro Reduction and Enzymatic Kinetic Resolution
Rivaroxaban, a benchmark direct factor Xa inhibitor, continues to motivate the search for safer, more robust and more sustainable synthetic routes. Here, complementary strategies for two key intermediates of its synthesis are reported: a continuous-flow reduction of 4-(4-nitrophenyl)morpholin-3-one (7) to the corresponding aniline (3), and a batch enzymatic kinetic resolution that gives access to (S)-glycidyl phthalimide (4). Catalytic hydrogenation in an H-Cube® cartridge reactor reached full conversion but suffered from selectivity loss, traced to accumulation of the hydroxylamine intermediate (13); a tube-in-tube/packed-bed configuration operating at 80 °C overcame this limitation, delivering full conversion with up to 99% selectivity at 40 min residence time (Rt) and surpassing the batch reference. As a metal-free alternative, the sodium dithionite reduction of the biphasic CHCl3/H2O system was successfully translated to a Chemtrix Kilo-Flow plate reactor, affording full conversion and higher than 99% selectivity at 20 min. Finally, the lipasemediated kinetic resolution of rac-17 with Lipase PS Amano IM (Burkholderia cepacia lipase, immobilized form), performed under batch conditions, was optimized to enantioselectivity (E) higher than 200. Together, these results establish an intensified route to rivaroxaban intermediates that couples a continuous-flow nitro reduction with an efficient batch biocatalytic resolution.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Process Intensification of Rivaroxaban Key Intermediates: Continuous-Flow Nitro Reduction and Enzymatic Kinetic Resolution
Rivaroxaban, a benchmark direct factor Xa inhibitor, continues to motivate the search for safer, more robust and more sustainable synthetic routes. Here, complementary strategies for two key intermediates of its synthesis are reported: a continuous-flow reduction of 4-(4-nitrophenyl)morpholin-3-one (7) to the corresponding aniline (3), and a batch enzymatic kinetic resolution that gives access to (S)-glycidyl phthalimide (4). Catalytic hydrogenation in an H-Cube® cartridge reactor reached full conversion but suffered from selectivity loss, traced to accumulation of the hydroxylamine intermediate (13); a tube-in-tube/packed-bed configuration operating at 80 °C overcame this limitation, delivering full conversion with up to 99% selectivity at 40 min residence time (Rt) and surpassing the batch reference. As a metal-free alternative, the sodium dithionite reduction of the biphasic CHCl3/H2O system was successfully translated to a Chemtrix Kilo-Flow plate reactor, affording full conversion and higher than 99% selectivity at 20 min. Finally, the lipasemediated kinetic resolution of rac-17 with Lipase PS Amano IM (Burkholderia cepacia lipase, immobilized form), performed under batch conditions, was optimized to enantioselectivity (E) higher than 200. Together, these results establish an intensified route to rivaroxaban intermediates that couples a continuous-flow nitro reduction with an efficient batch biocatalytic resolution.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
The 2025 FDA Small-Molecule Portfolio: Clinical Applications, Synthetic Approaches, Challenges, and Solutions
In 2025, the U.S. Food and Drug Administration (FDA) approved 46 new drugs comprising 31 small-molecule entities. These approvals represent significant milestones in the evolution of privileged structures and novel mechanisms of action, serving as invaluable leads for the development of next-generation therapeutics with enhanced efficacy. This article reviews the synthetic routes and clinical indications of these newly marketed drugs, highlighting their significance in the current pharmaceutical landscape.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
The 2025 FDA Small-Molecule Portfolio: Clinical Applications, Synthetic Approaches, Challenges, and Solutions
In 2025, the U.S. Food and Drug Administration (FDA) approved 46 new drugs comprising 31 small-molecule entities. These approvals represent significant milestones in the evolution of privileged structures and novel mechanisms of action, serving as invaluable leads for the development of next-generation therapeutics with enhanced efficacy. This article reviews the synthetic routes and clinical indications of these newly marketed drugs, highlighting their significance in the current pharmaceutical landscape.
- 1 April 2020
- Published by Elsevier in Molecular Catalysis
- Vol. 485, 110788
Studies on the laccases catalyzed oxidation of norbelladine like acetamides
- 1 April 2020
- Published by Elsevier in Molecular Catalysis
- Vol. 485, 110788
Studies on the laccases catalyzed oxidation of norbelladine like acetamides
- 22 January 2019
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 17 (6) , 1552-1557
Continuous-flow protocol for the synthesis of enantiomerically pure intermediates of anti epilepsy and anti tuberculosis active pharmaceutical ingredients
Continuous-flow production of chiral intermediates plays an important role in the development of building blocks for Active Pharmaceutical Ingredients (APIs), being α-amino acids and their derivatives widely applied as building blocks. In this work we developed two different strategies for the synthesis of intermediates used on the synthesis of levetiracetam/brivaracetam and ethambutol. The results obtained show that methionine methyl ester can be continuously converted to the desired ethambutol intermediate by RANEY® Nickel dessulfurization/reduction strategy whereas levetiracetam/brivaracetam intermediates could be synthesized by both RANEY® Nickel (without H2) and Pd/C–H2 approach or by photochemical desulfurization.
- 22 January 2019
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 17 (6) , 1552-1557
Continuous-flow protocol for the synthesis of enantiomerically pure intermediates of anti epilepsy and anti tuberculosis active pharmaceutical ingredients
Continuous-flow production of chiral intermediates plays an important role in the development of building blocks for Active Pharmaceutical Ingredients (APIs), being α-amino acids and their derivatives widely applied as building blocks. In this work we developed two different strategies for the synthesis of intermediates used on the synthesis of levetiracetam/brivaracetam and ethambutol. The results obtained show that methionine methyl ester can be continuously converted to the desired ethambutol intermediate by RANEY® Nickel dessulfurization/reduction strategy whereas levetiracetam/brivaracetam intermediates could be synthesized by both RANEY® Nickel (without H2) and Pd/C–H2 approach or by photochemical desulfurization.